Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Medicus Pharma Ltd ( (MDCX) ) is now available.
Medicus Pharma’s subsidiary Antev has amended its license agreement with UK-based medical research organization LifeArc for Teverelix, cutting the royalty rate on global net sales from roughly 4% to 2% and clarifying country-specific royalty terms while preserving exclusive worldwide rights, IP ownership, and full operational control over development, manufacturing, and commercialization. The streamlined, lower-cost royalty structure reflects scientific and intellectual property progress around Teverelix, strengthens the asset’s long-term economic profile and attractiveness for future partnerships, and supports Medicus’s strategy of de-risking programs through Phase 2 data to enable flexible global partnering in a potentially multibillion-dollar market for urologic and prostate cancer indications.
The most recent analyst rating on (MDCX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
Spark’s Take on MDCX Stock
According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral.
The score is driven primarily by weak financial performance (no revenue, widening losses, rising cash burn, and negative equity) and bearish technicals (below key moving averages with negative MACD). Valuation is constrained by negative earnings and no dividend support, partially offset by a modestly positive liquidity-related financing event.
To see Spark’s full report on MDCX stock, click here.
More about Medicus Pharma Ltd
Medicus Pharma Ltd. is a precision-guided biotech and life sciences company focused on advancing clinical development programs for novel, potentially disruptive therapeutic assets. Through its subsidiary Antev Ltd., the company is developing Teverelix, a next-generation long-acting GnRH antagonist targeting acute urinary retention relapse prevention and prostate cancer patients with high cardiovascular risk, collectively representing an estimated US$6 billion market opportunity. Medicus operates a partnering-focused model, aiming to advance select programs through Phase 2 proof-of-concept before pursuing licensing or strategic collaborations for late-stage development and commercialization.
Average Trading Volume: 312,977
Technical Sentiment Signal: Sell
Current Market Cap: $34.41M
For detailed information about MDCX stock, go to TipRanks’ Stock Analysis page.